Literature DB >> 22896701

A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Haydyn D T Mertens1, Magnus Kjaergaard, Simon Mysling, Henrik Gårdsvoll, Thomas J D Jørgensen, Dmitri I Svergun, Michael Ploug.   

Abstract

The urokinase-type plasminogen activator receptor (uPAR) provides a rendezvous between proteolytic degradation of the extracellular matrix and integrin-mediated adhesion to vitronectin. These processes are, however, tightly linked because the high affinity binding of urokinase regulates the binding of uPAR to matrix-embedded vitronectin. Although crystal structures exist to define the corresponding static bi- and trimolecular receptor complexes, it is evident that the dynamic property of uPAR plays a decisive role in its function. In the present study, we combine small angle x-ray scattering, hydrogen-deuterium exchange, and surface plasmon resonance to develop a structural model describing the allosteric regulation of uPAR. We show that the flexibility of its N-terminal domain provides the key for understanding this allosteric mechanism. Importantly, our model has direct implications for understanding uPAR-assisted cell adhesion and migration as well as for translational research, including targeted intervention therapy and non-invasive tumor imaging in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896701      PMCID: PMC3464537          DOI: 10.1074/jbc.M112.398404

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.

Authors:  Niko Schmiedeberg; Manfred Schmitt; Christian Rölz; Vincent Truffault; Martin Sukopp; Markus Bürgle; Olaf G Wilhelm; Wolfgang Schmalix; Viktor Magdolen; Horst Kessler
Journal:  J Med Chem       Date:  2002-11-07       Impact factor: 7.446

2.  Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

Authors:  Y Wei; J A Eble; Z Wang; J A Kreidberg; H A Chapman
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

3.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

4.  Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.

Authors:  M E Kroon; P Koolwijk; H van Goor; U H Weidle; A Collen; G van der Pluijm; V W van Hinsbergh
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.

Authors:  M Resnati; I Pallavicini; J M Wang; J Oppenheim; C N Serhan; M Romano; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

6.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.

Authors:  R W Stephens; H J Nielsen; I J Christensen; O Thorlacius-Ussing; S Sørensen; K Danø; N Brünner
Journal:  J Natl Cancer Inst       Date:  1999-05-19       Impact factor: 13.506

7.  Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.

Authors:  M Ploug; S Østergaard; H Gårdsvoll; K Kovalski; C Holst-Hansen; A Holm; L Ossowski; K Danø
Journal:  Biochemistry       Date:  2001-10-09       Impact factor: 3.162

Review 8.  Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.

Authors:  Michael Ploug
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

10.  The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  M Ploug; T Plesner; E Rønne; V Ellis; G Høyer-Hansen; N E Hansen; K Danø
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

View more
  25 in total

1.  The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Authors:  Henrik Gårdsvoll; Mette C Kriegbaum; Emil P Hertz; Warner Alpízar-Alpízar; Michael Ploug
Journal:  J Histochem Cytochem       Date:  2013-07-29       Impact factor: 2.479

2.  Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Authors:  Julie M Leth; Haydyn D T Mertens; Katrine Zinck Leth-Espensen; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2019-03-20       Impact factor: 5.157

3.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

4.  Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Authors:  Timmy Mani; Degang Liu; Donghui Zhou; Liwei Li; William Eric Knabe; Fang Wang; Kyungsoo Oh; Samy O Meroueh
Journal:  ChemMedChem       Date:  2013-10-02       Impact factor: 3.466

5.  Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain.

Authors:  Wanee Plengpanich; Stephen G Young; Weerapan Khovidhunkit; André Bensadoun; Hirankorn Karnman; Michael Ploug; Henrik Gårdsvoll; Calvin S Leung; Oludotun Adeyo; Mikael Larsson; Suwanna Muanpetch; Supannika Charoen; Loren G Fong; Sathit Niramitmahapanya; Anne P Beigneux
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

6.  Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

Authors:  Mahmoud A Al-Sha'er; Mohammad A Khanfar; Mutasem O Taha
Journal:  J Mol Model       Date:  2014-01-28       Impact factor: 1.810

7.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

8.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

9.  Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.

Authors:  Aaron M LeBeau; Sai Duriseti; Stephanie T Murphy; Francois Pepin; Byron Hann; Joe W Gray; Henry F VanBrocklin; Charles S Craik
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

10.  Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.

Authors:  Khuchtumur Bum-Erdene; Degang Liu; David Xu; Mona K Ghozayel; Samy O Meroueh
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.